Ocugen

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN (BBV152)

MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) this week announced positive results from the Phase 2/3, observer-blind, immuno-bridging and broadening study of its COVID-19 vaccine candidate, COVAXIN™ (BBV152; Clinicaltrials.gov, NCT05258669), …

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN (BBV152) Read More

cancer

Study: Cancer Patients Treated with Immunotherapy Can Safely Receive mRNA COVID-19 Vaccines

PLYMOUTH MEETING, PA — New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment. The researchers …

Study: Cancer Patients Treated with Immunotherapy Can Safely Receive mRNA COVID-19 Vaccines Read More